Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. director Adam Leo Stone has filed an initial Form 3 showing his stock option holdings in the company. The filing lists several options to buy Immatics ordinary shares with exercise prices of $10.0000, $11.0000, $7.9400, $11.4100, $12.0000, and $5.4400, expiring between June 30, 2030 and June 23, 2035.
Each option relates to a specific number of underlying ordinary shares, including 25,000, 15,000, 25,000, 25,000, 40,000 and 41,500 shares, all held directly. According to the footnotes, some of these options are already fully vested, while others are scheduled to vest 100% on June 24, 2025.
Immatics N.V. Chief Operating Officer Walter Steffen Martin reported his current equity holdings in the company. The filing lists multiple stock option grants over several years, including options on 200,000 ordinary shares at an exercise price of 9.3200 per share expiring on January 7, 2036. It also shows 50,000 restricted stock units, each convertible into one ordinary share, and 10,000 ordinary shares held directly. All entries are reported as direct ownership with no buy or sell transactions indicated.
Immatics N.V. Chief Business Officer Rainer Kramer filed a Form 3 reporting his equity holdings in the company. He directly holds multiple stock option awards over Ordinary Shares, including 22,868 options at an exercise price of $1.06 per share expiring on July 1, 2027, and several additional grants with exercise prices between $8.06 and $11.00 expiring from June 30, 2030 through January 7, 2036.
Footnotes indicate that some options are already fully vested, while others vest 25% on the first anniversary of their respective grant dates and then in equal quarterly installments over three years. Kramer also holds 40,000 restricted stock units, each representing one Ordinary Share, which vest in four equal annual installments on each anniversary of the January 8, 2026 grant date.
Immatics N.V. director Peter Alan Chambre filed an initial ownership report showing direct holdings of ordinary shares and multiple stock options. He directly holds 105,987 ordinary shares. In addition, he holds stock options over 25,000 ordinary shares at an exercise price of 7.9400 per share expiring on June 13, 2032, and 25,000 ordinary shares at 11.4100 per share expiring on June 26, 2033.
He also holds options over 40,000 ordinary shares at 12.0000 per share expiring on June 24, 2034, and 41,500 ordinary shares at 5.4400 per share expiring on June 23, 2035. Further positions include options over 236,974 ordinary shares at 10.0000 per share expiring on June 30, 2030, and 15,000 ordinary shares at 11.0000 per share expiring on December 8, 2031. Footnotes state that one set of options is fully vested and another set vests 100% on June 24, 2025.
Immatics N.V. director Michael G. Atieh filed an initial ownership report showing he holds several stock option awards over Immatics ordinary shares. The filing lists six option grants with exercise prices ranging from 5.44 to 12.00 and expirations between 2030 and 2035.
The footnotes state that some of these options are fully vested, while others vest 100% on June 24, 2025. The report only details existing derivative holdings and does not show any purchases or sales of Immatics shares.
Immatics N.V. filed an initial ownership report for Chief Innovation Officer Toni Michael Weinschenk, listing existing equity awards rather than new trades. The filing shows several stock option grants over ordinary shares, including options over 160,000 shares at an exercise price of $9.3200 expiring on January 7, 2036, and options over 7,850 shares at $1.0600 expiring on July 1, 2027. It also discloses 40,000 restricted stock units, each convertible into one ordinary share, vesting in four equal annual installments on each anniversary of the January 8, 2026 grant date.
Immatics N.V. received an initial ownership report from investment entities affiliated with Perceptive Advisors. The filing shows that Perceptive Life Sciences Master Fund directly holds 10,383,456 ordinary shares of Immatics, with Perceptive Advisors acting as investment advisor and Joseph Edelman as its managing member.
The report also lists multiple director stock options on Immatics ordinary shares, awarded to Adam Stone for his board service, with exercise prices between $5.44 and $12.00 and expirations from 2030 to 2035. The Master Fund has the right to receive this director compensation through a management fee offset. Perceptive Advisors and Mr. Edelman expressly disclaim beneficial ownership of these securities except to the extent of any indirect pecuniary interest.
Immatics N.V. director Mathias Hothum filed an initial ownership report showing his equity interests in the company. He indirectly holds 329,521 Ordinary Shares through MH-LT-Investments GmbH and reports no directly held Ordinary Shares. He also holds stock options over 25,000, 40,000, and 41,500 Ordinary Shares with exercise prices of $11.41, $12.00, and $5.44, expiring between 2033 and 2035.
Immatics N.V. reported a sharp shift to a net loss in 2025 as it accelerated investment in its PRAME oncology franchise while lapping a one‑time revenue benefit from a terminated collaboration. Revenue from collaboration agreements fell to €48.3 million in 2025 from €155.8 million in 2024, mainly because 2024 included accelerated non‑cash revenue from Bristol Myers Squibb collaboration terminations.
Research and development expenses rose to €183.8 million and general and administrative costs increased to €51.2 million, reflecting advancement of multiple PRAME cell therapies and bispecifics and early commercial preparations for lead therapy anzu‑cel (IMA203). Immatics posted a net loss of €196.4 million in 2025 versus a net profit of €15.2 million in 2024. Cash, cash equivalents and other financial assets totaled $551.4 million (€469.3 million) as of December 31, 2025, after significant operating cash use partly offset by $117.9 million in net equity offering proceeds.